Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in rats

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 3, 1996, Pages 197-207

  Wright, Jennifer D ^a   Ma, Tianwei ^a   Chu, Chukg K ^a   Boudinot, F Douglas ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Bioavailability; Discontinuous oral absorption; L FMAU; Pharmacokinetics

Indexed keywords

1 (2 FLUORO 5 METHYL BETA L ARABINOFURANOSYL)URACIL; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RAT;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; INJECTIONS, INTRAVENOUS; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029990509     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199604)17:3<197::AID-BDD948>3.0.CO;2-1     Document Type: Article

References (17)

1. C. K. Chu, T. Ma, K. Shanmuganathan, C. Wang, Y, Xiang, S. B. Pai, G.-Q. Yao, J.-P. Sommadossi and Y.-C. Cheng, Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B and Epstein-Barr virus. Antimicrob. Agents Chemother., 39, 979-981 (1995).
2. J. D. Wright, T. Ma, C. K. Chu and F. D. Boudinot, Pharmacokineties of 1-(2-deoxy-2-fluoro-5-methyl-β-L-arabinofuranosyl)-5-methyluracil (L.-FMAU) in rats. Pharm. Res., 12, 1350-1353 (1995).
3. D. C. Garg, D. J. Weidler and F. N. Eshelman, Ranitidine bioavailability and kinetics in normal male subjects. Clin. Pharmacol. Ther., 33, 445-452 (1983).
4. M. F. Williams, G. E. Dukes, W. Heizer, Y.-H. Han, D. J. Hermann, T. Lampkin and L. J. Hak, Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm. Res., 9, 1190-1194 (1992).
5. S. S. Walkenstein, J. W. Dubb, W. C. Randolph, W. J. Westlake, R. M. Stote and A. P. Intoccia, Bioavailability of cimetidine in man. Gastroenterology, 74, 360-364 (1978).
6. R. L. Oberle and G. L. Amidon, The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine. J. Pharmacokinet. Biopharm., 15, 529-545 (1987).
7. D. Brockmeier, H.-G. Grigoleit and H. Leonhardt, The absorption of piretanide from the gastro-intestinal tract is site-dependent. Eur. J. Clin. Pharmacol., 30, 79-82 (1986).
8. M.M. Hammarlund, L. K. Paalzow and B. Odlind, Pharmacokineties of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur. J. Clin. Pharmacol., 26, 197-207 (1984).
9. A. B. Suttle, G. M. Pollack and K. L. R. Brouwer, Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res., 9, 350-356 (1992).
10. C. H. Tann, P. R. Brodfuehrer, S. P. Brundidge, C. Sapino, Jr. and H. G. Howell, Fluorocarbohydrates in synthesis. An efficient synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (β-FIAU) and 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-thymine (β-FMAU). J. Org. Chem., 50, 3644-3647 (1985).
11. K. Shanmaganathan, T. Koudriakova, S. Nampalli, J. M. Gallo and C. K. Chu, Enhanced brain delivery of an anti-HIV nucleoside 2-F-ara-ddI by xanthine oxidase mediated biotransformation. J. Med. Chem., 37, 821-827 (1994).
12. M. L. Rocci and W. J. Jusko, LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Prog. Biomed., 16, 203-216 (1983).
13. K. C. Yeh and K. C. Kwan, A comparison of numerical integrating algorithms by trapezoidal, Lagrange and spline approximation. J. Pharmacokinet. Biopharm., 6, 79-98 (1978).
14. V. R. Jaragula, R. F. Schinazi, G. Fulcrand, Y. E. Kattan, D. C. Liotta and F. D. Boudinot, Pharmacokinetics of 5-carbonyl-2-deoxyuridine in rats. J. Pharm. Sci., 83, 1697-1699 (1994).
15. P. D. Miranda, T. C. Burnette and S. S. Good, Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab. Disposit., 18, 315-320 (1990).
16. X.-B. Kong, P. Vidai, W. P. Tong, J. Chiang, C. A. Gloff and T.-C. Chou, Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2-fluoro-5-ethyl-1-β-D-arabinofuranosyluracil in mice and rats. Antimicrob. Agents Chemother., 36, 1472-1477 (1992).
17. L. E. Gerlowski and R. K. Jain, Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci., 72, 1103-1126 (1983).